|
Name |
dankasterone A
|
Molecular Formula | C28H40O3 | |
IUPAC Name* |
(1R,9R,10R,13R,14R)-14-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-9,13-dimethyltetracyclo[8.7.0.01,13.04,9]heptadec-4-ene-3,6,17-trione
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CCC(=O)[C@@]23[C@@]1(CC[C@@H]2[C@]4(CCC(=O)C=C4C(=O)C3)C)C
|
|
InChI |
InChI=1S/C28H40O3/c1-17(2)18(3)7-8-19(4)21-9-10-25(31)28-16-23(30)22-15-20(29)11-13-26(22,5)24(28)12-14-27(21,28)6/h7-8,15,17-19,21,24H,9-14,16H2,1-6H3/b8-7+/t18-,19+,21+,24+,26-,27+,28-/m0/s1
|
|
InChIKey |
MHVQURVXZWOWCF-VODCKUOWSA-N
|
|
Synonyms |
dankasterone A; N134xvii; Numata 134-XVII (amagata); CHEMBL250639
|
|
CAS | NA | |
PubChem CID | 24179112 | |
ChEMBL ID | CHEMBL250639 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 424.6 | ALogp: | 5.3 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 51.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.508 |
Caco-2 Permeability: | -5.086 | MDCK Permeability: | 0.00002710 |
Pgp-inhibitor: | 0.993 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.592 |
30% Bioavailability (F30%): | 0.942 |
Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 86.82% |
Volume Distribution (VD): | 1.107 | Fu: | 1.73% |
CYP1A2-inhibitor: | 0.031 | CYP1A2-substrate: | 0.835 |
CYP2C19-inhibitor: | 0.551 | CYP2C19-substrate: | 0.953 |
CYP2C9-inhibitor: | 0.505 | CYP2C9-substrate: | 0.352 |
CYP2D6-inhibitor: | 0.032 | CYP2D6-substrate: | 0.335 |
CYP3A4-inhibitor: | 0.878 | CYP3A4-substrate: | 0.921 |
Clearance (CL): | 2.226 | Half-life (T1/2): | 0.703 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.284 |
Drug-inuced Liver Injury (DILI): | 0.135 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.828 | Maximum Recommended Daily Dose: | 0.882 |
Skin Sensitization: | 0.688 | Carcinogencity: | 0.032 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.057 |
Respiratory Toxicity: | 0.702 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003940 | 0.789 | D06JPB | 0.367 | ||||
ENC002481 | 0.680 | D0G8BV | 0.358 | ||||
ENC004615 | 0.625 | D0G8OC | 0.355 | ||||
ENC004905 | 0.615 | D0G5CF | 0.350 | ||||
ENC001861 | 0.547 | D04GJN | 0.345 | ||||
ENC004737 | 0.547 | D0IX6I | 0.336 | ||||
ENC004022 | 0.547 | D0Z1XD | 0.330 | ||||
ENC002985 | 0.532 | D0X4RS | 0.325 | ||||
ENC002188 | 0.532 | D0I2SD | 0.322 | ||||
ENC001990 | 0.527 | D0EP0C | 0.320 |